[Multicenter comparative study of meropenem, a new carbapenemic preparation, administered intramuscularly. Treatment of respiratory and urinary infections in hospitalized patients]l.
263 hospitalized patients were enrolled in a multicentre study to assess efficacy and safety of i. m. meropenem, compared to ceftazidime, in the treatment of lower respiratory tract infections and urinary infections as well. Meropenem, administered at a dose of 500 mg tid, was therapeutically equivalent to the reference agent (1000 mg tid in RTI's and 500 mg tid in UTI's) in both indications. The two treatments were well tolerated, without any serious local or systemic side effect.
Lechi
A
A
Cattedra di Medicina Interna, Università degli Studi di Verona.
Montesi
G
G
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002442:Ceftazidime / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D000077731:Meropenem; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013845:Thienamycins / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D013845:Thienamycins; D002442:Ceftazidime; D000077731:Meropenem